The estimated Net Worth of Bruce Daugherty is at least $15 Тысяча dollars as of 21 June 2016. Dr Daugherty owns over 100,000 units of Tonix Pharmaceuticals Corp stock worth over $15,000 and over the last 12 years he sold TNXP stock worth over $0.
Sign up
Dr D TNXP stock SEC Form 4 insiders trading
Dr has made over 6 trades of the Tonix Pharmaceuticals Corp stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of TNXP stock worth $200,000 on 21 June 2016.
The largest trade he's ever made was buying 100,000 units of Tonix Pharmaceuticals Corp stock on 21 June 2016 worth over $200,000. On average, Dr trades about 14,321 units every 80 days since 2013. As of 21 June 2016 he still owns at least 100,000 units of Tonix Pharmaceuticals Corp stock.
You can see the complete history of Dr Daugherty stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Bruce L. Daugherty M.B.A., Ph.D. biography
Dr. Bruce L. Daugherty M.B.A., Ph.D. is the Exec. VP of Research at Tonix Pharmaceuticals Corp.
How old is Dr D?
Dr D is 63, he's been the Exec. VP of Research of Tonix Pharmaceuticals Corp since . There are 4 older and 9 younger executives at Tonix Pharmaceuticals Corp. The oldest executive at Tonix Pharmaceuticals Holding Corp is Adeoye Olukotun, 75, who is the Independent Director.
What's Dr D's mailing address?
Bruce's mailing address filed with the SEC is C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK, NY, 10022.
Insiders trading at Tonix Pharmaceuticals Corp
Over the last 12 years, insiders at Tonix Pharmaceuticals Corp have traded over $155,884 worth of Tonix Pharmaceuticals Corp stock and bought 1,820,071 units worth $3,399,062 . The most active insiders traders include Ernest Mario, Seth Lederman и Bruce Daugherty. On average, Tonix Pharmaceuticals Corp executives and independent directors trade stock every 32 days with the average trade being worth of $2,734. The most recent stock trade was executed by Seth Lederman on 29 June 2022, trading 20,000 units of TNXP stock currently worth $34,200.
What does Tonix Pharmaceuticals Corp do?
tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.
What does Tonix Pharmaceuticals Corp's logo look like?
Complete history of Dr Daugherty stock trades at Tonix Pharmaceuticals Corp
Tonix Pharmaceuticals Corp executives and stock owners
Tonix Pharmaceuticals Corp executives and other stock owners filed with the SEC include:
-
Seth Lederman,
Chairman of the Board, President, Chief Executive Officer -
Dr. Seth Lederman M.D.,
Co-Founder, Pres, CEO & Chairman -
Dr. Seth Lederman,
Co-Founder, Pres, CEO & Chairman -
Dr. Gregory M. Sullivan M.D.,
Chief Medical Officer & Sec. -
Gregory Sullivan,
Secretary, Chief Medical Officer -
Bradley Saenger CPA, CPA,
CFO & Treasurer -
Bradley Saenger,
Chief Financial Officer, Treasurer -
Richard Bagger,
Director -
Herbert Harris,
Executive Vice President - Translational Medicine -
David Grange,
Independent Director -
Margaret Bell,
Independent Director -
James Treco,
Lead Independent Director -
Adeoye Olukotun,
Independent Director -
Daniel Goodman,
Independent Director -
Jessica Morris,
Chief Operating Officer -
Dr. Sina Bavari Ph.D.,
Exec. VP of Infectious Disease R&D -
Dr. Anthony Macaluso Ph.D.,
Exec. VP of Strategic Devel. -
Dr. Darryl Rideout Ph.D.,
Exec. VP of Experimental Chemistry -
Siobhan Fogarty B.Sc., M.Sc.,
Exec. VP of Product Devel. -
Dr. Bruce L. Daugherty M.B.A., Ph.D.,
Exec. VP of Research -
Dr. Herbert W. Harris M.D., Ph.D.,
Exec. VP of Translational Medicine -
Dr. R. Michael Gendreau,
Consultant -
Dr. Daniel J. Clauw M.D.,
Consultant -
Dr. Ronald R. Notvest,
Exec. VP of Commercial Planning and Devel. -
Jessica Edgar Morris,
Chief Operating Officer -
Charles E Iv Mather,
Director -
Ernest Mario,
Director -
John B Rhodes,
Director -
Samuel R Saks,
Director -
Patrick P Grace,
Director -
Bruce Daugherty,
See Remarks -
Stuart Davidson,
Director -
Donald J Kellerman,
See Remarks -
Leland Gershell,
CFO and Treasurer -
Carolyn E. Taylor,
Director -
Richard Newcomb Stillwell,
Director